Ixabepilone (Bristol-Myers Squibb), a semi-synthetic analog of a new class of cytotoxic agents known as epothi-lo­nes, has been shown to have promising efficacy and a manage­able safety profile in patients with metastatic breast cancer highly resistant to standard chemotherapy including an anthracycline, a taxane, and capecitabine, according to a presentation given at the 42nd annual meeting of the American Society of Clinical Oncology.
Go to Previous Page
Go to Next Page